MY210523A - A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease - Google Patents

A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease

Info

Publication number
MY210523A
MY210523A MYPI2021000486A MYPI2021000486A MY210523A MY 210523 A MY210523 A MY 210523A MY PI2021000486 A MYPI2021000486 A MY PI2021000486A MY PI2021000486 A MYPI2021000486 A MY PI2021000486A MY 210523 A MY210523 A MY 210523A
Authority
MY
Malaysia
Prior art keywords
related disease
prevention
treating
preventing
treatment
Prior art date
Application number
MYPI2021000486A
Inventor
Joy C Hsu
Erica Winter
Jun-Ichi Nishimura
Keisuke Gotanda
Kenji Shinomiya
Original Assignee
Univ Osaka
Hoffmann La Roche
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Osaka, Hoffmann La Roche, Chugai Pharmaceutical Co Ltd filed Critical Univ Osaka
Publication of MY210523A publication Critical patent/MY210523A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical compositions for use in the treatment or prevention of a C5-related disease and methods for treating or preventing a C5-related disease. The present invention further relates to dosages and administrations of anti-C5 antibody or pharmaceutical compositions containing the anti-C5 antibody.
MYPI2021000486A 2018-08-01 2019-08-01 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease MY210523A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862713211P 2018-08-01 2018-08-01
US201862764952P 2018-08-17 2018-08-17
US201862760204P 2018-11-13 2018-11-13
PCT/JP2019/030283 WO2020027279A1 (en) 2018-08-01 2019-08-01 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease

Publications (1)

Publication Number Publication Date
MY210523A true MY210523A (en) 2025-09-29

Family

ID=67660420

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021000486A MY210523A (en) 2018-08-01 2019-08-01 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease

Country Status (23)

Country Link
US (1) US20210301004A1 (en)
EP (2) EP4445913A3 (en)
JP (4) JP6672516B2 (en)
KR (5) KR20200033225A (en)
CN (1) CN112512563A (en)
AU (2) AU2019315213B2 (en)
BR (1) BR112021001655A2 (en)
CA (1) CA3107618A1 (en)
CR (1) CR20210103A (en)
DE (1) DE112019003835T5 (en)
ES (1) ES2980137T3 (en)
HR (1) HRP20240823T1 (en)
HU (1) HUE067057T2 (en)
IL (2) IL324626A (en)
MX (2) MX2021000516A (en)
MY (1) MY210523A (en)
PH (1) PH12021550226A1 (en)
PL (1) PL3829628T3 (en)
RS (1) RS65630B1 (en)
SG (1) SG10202002898RA (en)
SM (1) SMT202400271T1 (en)
TW (2) TWI701041B (en)
WO (1) WO2020027279A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TW201920257A (en) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
TWI654203B (en) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha Antibodies with calcium-dependent antigen binding ability
MX2017005774A (en) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use.
EA201791366A1 (en) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся ANTIBODIES TO C5 AND METHODS OF THEIR APPLICATION
CN114773469B (en) 2015-02-05 2025-12-19 中外制药株式会社 Antibodies comprising ion concentration-dependent antigen binding domains, variants of the FC region, IL-8-binding antibodies and uses thereof
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
CN116271014A (en) 2016-08-05 2023-06-23 中外制药株式会社 Composition for preventing or treating IL-8 related diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド Modifications of or for denatured antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ATE449791T1 (en) 2000-10-10 2009-12-15 Genentech Inc INHIBITION OF C5 COMPLEMENT ACTIVATION FOR THE TREATMENT AND PREVENTION OF XENO-TRANSPLANT OR ACUTE VASCULAR REJECTION
MXPA04001301A (en) 2001-08-17 2004-07-08 Tanox Inc Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b.
ITMI20021527A1 (en) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche C5 COMPONENT ANTIBODIES OF COMPLEMENT AND THEIR USE
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and uses thereof
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
HUE066795T2 (en) 2006-03-15 2024-09-28 Alexion Pharma Inc Treatment of patients with paroxysmal nocturnal haemoglobinuria with a complement inhibitor
TW201920257A (en) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
PY09026846A (en) 2008-08-05 2015-09-01 Novartis Ag COMPOSITIONS AND METHODS FOR ANTIBODIES THAT TARGET THE C5 COMPLEMENT PROTEIN
JP6223659B2 (en) 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ, インコーポレイテッド Methods and compositions for treating complement related disorders
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
TWI667346B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
BR112015018438A2 (en) * 2013-01-31 2017-07-18 Seoul Nat Univ R&Db Foundation c5 antibody and method for preventing and treating complement-related diseases
EA201791366A1 (en) * 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся ANTIBODIES TO C5 AND METHODS OF THEIR APPLICATION
TWI759261B (en) * 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Use of IL-6 receptor antibody for preparing pharmaceutical composition
US20190023775A1 (en) * 2016-01-11 2019-01-24 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
MA53248A (en) 2016-01-25 2022-02-16 Takeda Pharmaceuticals Co PH-ENHANCED ANTI-C5 ANTIBODIES
JP7518764B2 (en) * 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ, インコーポレイテッド Dosage and Administration of Anti-C5 Antibodies for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
BR112020010916A2 (en) * 2017-12-04 2020-11-17 Ra Pharmaceuticals, Inc modulators of complement activity

Also Published As

Publication number Publication date
SG10202002898RA (en) 2020-05-28
KR20210037743A (en) 2021-04-06
EP3829628A1 (en) 2021-06-09
DE112019003835T5 (en) 2021-05-27
IL280475B2 (en) 2026-04-01
KR20200033348A (en) 2020-03-27
KR20200033225A (en) 2020-03-27
JP2020019769A (en) 2020-02-06
HRP20240823T1 (en) 2024-09-27
EP4445913A2 (en) 2024-10-16
TWI701041B (en) 2020-08-11
EP3829628C0 (en) 2024-05-15
JP6672533B1 (en) 2020-03-25
IL324626A (en) 2026-01-01
AU2019315213B2 (en) 2024-05-02
TW202019467A (en) 2020-06-01
BR112021001655A2 (en) 2021-05-04
KR20210038697A (en) 2021-04-07
SMT202400271T1 (en) 2024-07-09
TW202024128A (en) 2020-07-01
EP3829628B1 (en) 2024-05-15
JP2020079331A (en) 2020-05-28
ES2980137T3 (en) 2024-09-30
CR20210103A (en) 2021-03-22
JP2025065367A (en) 2025-04-17
US20210301004A1 (en) 2021-09-30
JP2020073608A (en) 2020-05-14
IL280475B1 (en) 2025-12-01
HUE067057T2 (en) 2024-09-28
PH12021550226A1 (en) 2021-10-11
JP6672516B2 (en) 2020-03-25
TWI704157B (en) 2020-09-11
IL280475A (en) 2021-03-01
CA3107618A1 (en) 2020-02-06
CN112512563A (en) 2021-03-16
AU2024205486A1 (en) 2024-08-22
WO2020027279A1 (en) 2020-02-06
PL3829628T3 (en) 2024-08-19
MX2021000516A (en) 2021-04-12
MX2025010400A (en) 2025-10-01
KR20240115904A (en) 2024-07-26
EP4445913A3 (en) 2025-01-01
RS65630B1 (en) 2024-07-31
AU2019315213A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
PH12019501706A1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
PH12021550226A1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
PH12018500642A1 (en) Anti-garp antibody
MX2020001774A (en) Compositions and methods for treating cholestatic disease.
MX2022004072A (en) Factor xi antibodies and methods of use.
EA201891853A1 (en) METHODS OF TREATMENT OR PREVENTION OF ATHEROSCLEROSIS BY INTRODUCING ANGPTL3 INHIBITOR
MX2017010982A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
EA202090944A1 (en) ANTI-CD3-ANTIBODY AND A PHARMACEUTICAL COMPOSITION FOR TREATING ONCOLOGICAL DISEASES, CONTAINING IT
EA036102B9 (en) Glycotargeting therapeutics
EP4384219A4 (en) COMPOSITIONS, DOSES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
PH12016501820A1 (en) Il-21 antibodies
EA201990988A1 (en) ANTIBODIES AGAINST CHIKV AND WAYS OF THEIR APPLICATION
MX2018009662A (en) Method and pharmaceutical composition for treatment of neurodegeneration.
MX2020009496A (en) Method for treating asthma or allergic disease.
MX2020001164A (en) Composition for use in the prevention and/or treatment of oncologic treatment induced orogastrointestinal mucositis.
MX2017000886A (en) TREATMENT WITH CIS-CLOMIFENO OF SOFOCOS AND LOSS OSEA INDUITED BY PRIVACY OF ANDROGEN THERAPEUTICS.
EP3955927A4 (en) COMPOSITIONS AND METHODS FOR TREATING, AMOUNTING AND PREVENTING H. PYLORI INFECTIONS
MX2020012805A (en) Compounds for pain treatment, compositions comprising same, and methods of using same.
MX2021001228A (en) Composition for use in the prevention and/or treatment of the genitourinary mucosa.
SG10201705954VA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2022000317A (en) Highly potent antibodies binding to death receptor 4 and death receptor 5.
WO2021136841A3 (en) Pharmaceutical composition for the prevention or treatment of post-surgical pain
MX2021001393A (en) Compositions for the treatment of graft versus host disease.
SG10201700775YA (en) A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease
WO2018030881A3 (en) Use of thyroid hormone for treatment of choroidal disease